TABLE A1.
Median Treatment Durations and Median Cumulative Dose Intensities (safety-evaluable population)
| Treatment or Dose | Inavo + Palbo + Letro Arm (n = 33) | Inavo + Palbo + Fulv Arm (n = 20) |
|---|---|---|
| Treatment duration, months (range) | ||
| Inavo | 15.7 (1.3-66.5) | 20.8 (1.8-47.6) |
| Palbo | 15.7 (1.4-66.3) | 20.8 (1.8-47.6) |
| Letro | 17.0 (1.4-66.5) | — |
| Fulv | — | 20.2 (0.9-47.4) |
| Median cumulative dose intensities,a % (range) | ||
| Inavo | 95.3 (22.7-238.6) | 90.5 (43.2-99.8) |
| Palbo | 81.3 (43.6-101.0) | 80.6 (48.3-99.4) |
| Letro | 98.0 (76.5-100.0) | — |
| Fulv | — | 95.4 (30.8-225.6) |
Abbreviations: Fulv, fulvestrant; Inavo, inavolisib; Letro, letrozole; Palbo, palbociclib.
a
The cumulative dose intensity is the proportion of the total dose administered divided by the total dose planned to be administered. Some cumulative dose intensities for Inavo may be above 100% due to intrapatient dose escalation in stage I.